Zeltia S.A.: Report at 30 June 2005

Madrid (ots/PRNewswire) - PharmaMar:

- Orphan Drug designation granted by the FDA to Yondelis for the treatment of ovarian cancer in April.

- Patient recruitment ongoing for the Phase III trial of Yondelis in ovarian cancer.

- Promising results of Phase II trial of Yondelis in prostate cancer released at ASCO.

- PharmaMar received 1 million dollars for complying with a milestone under the licensing and co-development contract with Johnson & Johnson.

- Patient enrolment goal reached in the Phase II study of Yondelis in STS

Other:

- Zeltia increased capital, raising 65 million euro.

- Group revenues amounted to 39 million euro.

- The net cash position (cash + cash equivalents - short-term bank debt) amounted to 115 million euro.

For further information please refer to www.zeltia.com

Isabel Lozano
CEO
PharmaMar, S.A..U.
C/ Reyes, 1. Colmenar Viejo
Madrid
Telephone: +34-91-846-60-00
Catherine Moukheibir
Head of Capital Market
Strategy
Zeltia, S.A.
José Abascal, 2. Madrid
Telephone: +34-91-444-45-00
Ma Luisa de Francia
CFO
Zeltia, S.A.
José Abascal, 2. Madrid
Telephone: +34-91-444-45-00

Rückfragen & Kontakt:

Isabel Lozano, CEO, PharmaMar, S.A..U., C/ Reyes, 1. Colmenar Viejo,
Madrid, Telephone: +34-91-846-60-00; Catherine Moukheibir, Head of
Capital Market, Strategy, Zeltia, S.A., José Abascal, 2. Madrid,
Telephone: +34-91-444-45-00; Ma Luisa de Francia, CFO, Zeltia, S.A.,
José Abascal, 2. Madrid, Telephone: +34-91-444-45-00

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | PRN0003